Insulet (PODD) Surpasses Q4 Earnings and Revenue Estimates
Insulet (PODD) came out with quarterly earnings of $1.40 per share, beating the Zacks Consensus Estimate of $0.67 per share. This compares to earnings of $0.55 per share a year ago.
Insulet's (PODD) Omnipod 5 Gets CE Mark for Added Compatibility
Insulet's (PODD) tubeless automated insulin delivery system's CE mark approval with multiple CGM sensor brands is likely to serve a wider patient pool.
Insulet (PODD) Gains From Product Innovation, Global Expansion
Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.
Here's Why Insulet (PODD) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
How to Find the Best Top-Ranked Stocks to Buy in 2024
Here is how to utilize the Filtered Zacks Rank 5 Stock Screen to help find potentially winning stocks to buy to close out December and throughout 2024.
Insulet (PODD) Up 31.5% Since Q3 Earnings: What's Driving It?
Insulet (PODD) continues to gain from the strong adoption of Ommipod 5 and market expansion.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Surging Earnings Estimates Signal Upside for Insulet (PODD) Stock
Insulet (PODD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Insulet (PODD) Banks on Omnipod for Consistent Market Share Gain
Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.
Wall Street Analysts Think Insulet (PODD) Could Surge 53.28%: Read This Before Placing a Bet
The consensus price target hints at a 53.3% upside potential for Insulet (PODD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima...
Insulet (PODD) Q3 Earnings Beat, 2023 Sales Growth View Up
Insulet's (PODD) third-quarter 2023 revenues increase year over year as a result of continued high demand for Omnipod 5.
Insulet (PODD) stock up 14% on positive earnings and growth forecast
Shares of medical device company Insulet Corporation (NASDAQ: PODD) witnessed a remarkable surge, jumping by 14% on Friday in response to the company's recent earnings report. The substantial incre...
Insulet Stock Rallies on Revenue Boost. It's a 'Misunderstood Growth Name.
The automated insulin technology developer posts third-quarter revenue of $432.7 million, compared with $340.8 million a year earlier.
Insulet shares rebound after results top estimates
Insulet Corp. shares PODD, +1.98% climbed 10% premarket on Friday after the insulin pump maker late Thursday reported third-quarter results that beat expectations and aimed to dispel some investor ...
Related Companies